Φορτώνει......
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
BACKGROUND: Achieving optimal symptom control with minimal side effects is a major goal in clinical practice. Dual-agent dopamine receptor agonist (DA) therapy in Parkinson’s disease (PD) may represent a promising approach to treatment, as the combination of different pharmacokinetic/pharmacological...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | BMC Neurol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4364324/ https://ncbi.nlm.nih.gov/pubmed/25879416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0267-7 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|